TipRanks on MSN
ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment
ArriVent BioPharma, Inc. (($AVBP)) announced an update on their ongoing clinical study. ArriVent BioPharma, Inc. is conducting a pivotal clinical ...
16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...
Hosted on MSN
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations
NEWTOWN SQUARE, PA – ArriVent BioPharma, Inc. (Nasdaq: AVBP) presented final proof-of-concept results from its global Phase 1b FURTHER trial of firmonertinib, an oral targeted therapy for patients ...
16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback